Laboratoriniai tyrimai - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 90,077 | 153,825 | 276,830 | 228,225 | 221,460 | 268,069 | 208,981 | 327,745 |
| Profit before tax | -4,596 | 20,019 | 113,960 | 48,081 | 32,241 | 47,198 | -33,905 | 66,229 |
| Net profit | -4,596 | 18,698 | 108,019 | 46,253 | 30,576 | 36,712 | -33,905 | 58,850 |
| Equity | 21,894 | 40,592 | 73,611 | 49,439 | 80,015 | 60,727 | 26,823 | 85,673 |
| Liabilities | 79,980 | 95,274 | 96,949 | 112,444 | 78,366 | 123,177 | 213,700 | 201,595 |
| Non-current assets | 64,234 | 74,145 | 78,621 | 86,337 | 81,036 | 66,961 | 184,788 | 144,018 |
| Current assets | 36,176 | 60,745 | 91,389 | 73,438 | 75,842 | 115,156 | 53,462 | 141,668 |
| Total assets | 100,410 | 134,890 | 170,010 | 159,775 | 156,878 | 182,117 | 238,250 | 285,686 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 66,122 | 62,407 | 55,722 |
| Social insurance contributions | - | - | - | - | - | 3,111 | 12,527 | 27,562 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +8.8% | +70.8% | +80.0% | -17.6% | -3.0% | +21.0% | -22.0% | +56.8% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -4.6% | 13.9% | 63.5% | 28.9% | 19.5% | 20.2% | -14.2% | 20.6% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | -21.0% | 46.1% | 146.7% | 93.6% | 38.2% | 60.5% | -126.4% | 68.7% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -5.1% | 12.2% | 39.0% | 20.3% | 13.8% | 13.7% | -16.2% | 18.0% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | -5.1% | 13.0% | 41.2% | 21.1% | 14.6% | 17.6% | -16.2% | 20.2% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 3.7 | 2.3 | 1.3 | 2.3 | 1.0 | 2.0 | 8.0 | 2.4 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 30,026 | 34,828 | 50,333 | 46,418 | 54,236 | 86,942 | 61,165 | 80,265 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Laboratoriniai tyrimai - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-02-18 | 2026-03-11 | 0.30 |
| 2026-02-12 | 2026-02-12 | 0.30 |
| 2026-01-05 | 2026-01-06 | 3.97 |
| 2025-12-16 | 2025-12-18 | 280.14 |
| 2022-11-21 | 2022-12-06 | 0.01 |
| 2022-11-17 | 2022-11-18 | 0.01 |
| 2022-10-18 | 2022-11-13 | 0.01 |
| 2022-09-16 | 2022-10-13 | 0.01 |
| 2022-08-23 | 2022-09-11 | 0.01 |
| 2022-07-25 | 2022-08-15 | 0.01 |
Laboratoriniai tyrimai - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-01-08 | 2025-01-23 | 0.05 |
| 2024-12-14 | 2024-12-16 | 0.05 |
| 2024-10-04 | 2024-10-13 | 0.05 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Laboratoriniai tyrimai, UAB (code 303329655) is a Private Limited Liability Company engaged in testing and analysis of materials. In 2025, the company generated revenue of €327.7K and net profit of €58.9K, with a profit margin of 18.0%. This marked a strong improvement from 2024, when revenue was €209.0K and the company posted a net loss of €33.9K, after a profitable 2023 with revenue of €268.1K and net profit of €36.7K. Over the two-year period from 2023 to 2025, revenue increased by 22.3%, while year-on-year growth in 2025 reached 56.8%. The balance sheet also strengthened in 2025: total assets rose to €285.7K, equity increased to €85.7K, and liabilities stood at €201.6K. Long-term assets were €144.0K and short-term assets €141.7K. Key efficiency indicators were solid, with ROE at 68.7%, ROA at 20.6%, debt-to-equity at 2.35, and asset turnover at 1.15x. Revenue per employee was €81.9K, indicating reasonable productivity for the latest financial year.